{"entity":{"id":"vortex-therapeutics","kind":"company","name":"Vortex Therapeutics","aka":["VORTEX THERAPEUTICS INC"],"tldr":"Vortex Therapeutics is an Illinois company making tablets that block MYC, a protein that drives the growth of many cancers and has had no direct drug. Its lead medicine, VOR-001, is being prepared for first trials in people.","summary":"Vortex Therapeutics, of Lombard, Illinois, develops small-molecule inhibitors of intrinsically disordered proteins. Its most advanced programme, VOR-001, is described as a direct, orally bioavailable small-molecule MYC inhibitor that the company has selected to advance to an investigational new drug application; the company reports tumour regression in a hepatocellular carcinoma model in mice and has developed a response signature for selecting patients. In fiscal year 2026 the National Cancer Institute funded its SBIR project on a novel MYC inhibitor for cancer therapy (5R44CA302283-02, USD 1,142,245).","asOf":"2026-11-04","links":[{"label":"Official website","url":"https://vortextherapeutics.com/"},{"label":"Pipeline","url":"https://vortextherapeutics.com/pipeline-vortex-therapeutics/"},{"label":"NIH RePORTER: 5R44CA302283-02","url":"https://reporter.nih.gov/project-details/11419007"}],"tags":[],"related":[],"cancers":[],"sections":["targeted-therapy"],"technologies":[],"targets":["myc-gene"],"drugs":["vor-001"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Read on vortextherapeutics.com (home, science and pipeline pages) and the NIH RePORTER record on 4 November 2026. Efficacy and safety statements are the company's own preclinical findings."],"hq":"Lombard, IL","country":"US","companyType":"biotech","website":"https://vortextherapeutics.com/","stage":"startup","investors":[],"funding":[{"round":"Grant","year":2026,"amountUsd":1142245,"source":"https://reporter.nih.gov/project-details/11419007","note":"NCI SBIR (R44) award 5R44CA302283-02: Development of a novel MYC inhibitor for cancer therapy"}]},"route":"/companies/vortex-therapeutics/","neighbours":{"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"target":[{"id":"myc-gene","kind":"target","name":"MYC","route":"/targets/myc-gene/"}],"drug":[{"id":"vor-001","kind":"drug","name":"VOR-001","route":"/drugs/vor-001/"}]}}